Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis

详细信息    查看全文

• 作者：Yuiko Sato^a ; ^b ; ¹ ; Toshimi Tando^a ; ¹ ; Mayu Morita^d ; ¹ ; Kana Miyamoto^a ; ¹ ; Tami Kobayashi^a ; ^c ; Ryuichi Watanabe^a ; Takatsugu Oike^a ; Morio Matsumoto^a ; Masaya Nakamura^a ; Takeshi Miyamoto^a ; ^b ; ^{miyamoto@z5.keio.jp}
• 关键词：Male osteoporosis ; Selective estrogen receptor modulators ; Raloxifene ; Bazedoxifene ; Tamoxifen ; Eldecalcitol
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2017
• 出版时间：22 January 2017
• 年：2017
• 卷：482
• 期：4
• 页码：1430-1436
• 全文大小：2371 K
• 卷排序：482

文摘

Raloxifene treatment blocks bone loss in male osteoporosis mouse models. Orchiectomy-induced bone loss in mice is abrogated by bazedoxifene. Male osteoporosis in mouse models is inhibited by tamoxifen. Low bone mass in male osteoporosis mice is ameliorated by eldecalcitol.